Physician profile
G Stephen Cleves
NPI 1023086386
$6,473.43
in general payments reported to CMS, 2019-2025
40 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $325 · 2021: $168 · 2022: $590 · 2023: $1,375 · 2024: $1,667 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,440.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $972.90 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $709.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $537.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $486.73 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $466.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $462.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $298.01 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.86 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $206.23 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $190.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $182.82 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $147.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.32 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $122.96 | 2022-2025 | |
| Allergan, INC. | $111.01 | 2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw G Cleves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.